INVESTOR RELATIONS

INVESTOR OVERVIEW

INVESTOR OVERVIEW

There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary ViewRay's MRIdian Linac Awarded French Tender for MR Image-guided Radiation Therapy
UNICANCER to Bring Next Generation Radiotherapy to Centre Georges-François Leclerc (CGFL) CLEVELAND , July 11, 2018   /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced that the company's MRIdian® Linac has been selected for installation at Centre Georges-François Leclerc (CGFL) in Dijon,
Toggle Summary Loyola Medicine/Palos Health Installs ViewRay's MRIdian Linac System for MR Image-Guided Radiation Therapy
Chicago-Area Provider Becomes First Community Hospital in the U.S. with ViewRay's Next Generation Linear Accelerator-Based System CLEVELAND , July 9, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that Palos Health , in partnership with Loyola Medicine, has installed ViewRay's
Toggle Summary University of Wisconsin Begins Patient Treatments with ViewRay's MRIdian Linac
Becomes the First Hospital to Upgrade Previous Generation MRIdian to Advanced Linear Accelerator-based System CLEVELAND , June 21, 2018 /PRNewswire/   -- ViewRay, Inc. (Nasdaq: VRAY) announced today that University of Wisconsin Carbone Cancer Center in Madison, Wisconsin , has begun patient
Toggle Summary Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian System
Next Generation Cancer Therapy Enables Delivery of Higher, Potentially More Effective Radiation Dose Regimens CLEVELAND , June 13, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

ViewRay

ViewRay Headquarters

2 Thermo Fisher Way
Oakwood Village, Ohio 44146 +1 (440) 703-3210
info@viewray.com